Kristine Pemberton

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

Medicine, Oncology, Palliative Oncology +9

Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer

Karim Fizazi, Celestia S. Higano, Joel B. Nelson et al. · Journal of Clinical Oncology · 2013 · 215 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Tanja Čufer, Eduard Vrdoljak, Rabab Gaafar et al. · Anti-Cancer Drugs · 2006 · 151 citations

Medicine, Oncology, Pharmacotherapy +16

Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone

Joel B. Nelson, Karim Fizazi, Kurt Miller et al. · Cancer · 2012 · 112 citations

Medicine, Oncology, Pharmacology +17

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

K. Miller, Judd W. Moul, Martin Gleave et al. · Prostate Cancer and Prostatic Diseases · 2013 · 91 citations

Medicine, Oncology, Pharmacology +10